MARCKSL1: A Potential Drug Target and Biomarker (G65108)

Target Name: MARCKSL1

NCBI ID: G65108

MARCKSL1

MARCKSL1: A Potential Drug Target and Biomarker

Marcksl1, a gene that encodes a protein known as MARCKS1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. MARCKS1 plays a crucial role in the development and maintenance of tight junctions, which are a type of cell-cell barrier that helps to maintain tissue structure and function.

The tight junction is a specialized barrier that separates cells from their surrounding environment, allowing substances to come in and out while keeping harmful particles out. MARCKS1 helps to regulate the movement of proteins and other molecules through the tight junction, ensuring that essential substances can enter or leave cells while keeping everything else out.

MARCKS1 has been shown to be involved in various signaling pathways that are important for cell growth, differentiation, and survival. It has been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

As a drug target, MARCKS1 has the potential to be used to treat a wide range of conditions. For example, MARCKS1 has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. By targeting MARCKS1, researchers and doctors may be able to develop new treatments for these debilitating conditions.

In addition to its potential as a drug target, MARCKS1 has also been identified as a potential biomarker for certain diseases. The tight junction is a critical barrier that helps to keep harmful substances out of cells, so changes in the tight junction can be an indication of certain diseases. By studying the effects of drugs on MARCKS1, researchers may be able to develop new diagnostic tests for diseases that affect the tight junction.

One of the challenges in studying MARCKS1 as a drug target and biomarker is understanding how the tight junction is regulated by various factors, including genetic and environmental factors. However, research into MARCKS1 is ongoing, and as more is learned about its role in these processes, researchers may be able to develop new treatments and diagnostic tests for a wide range of conditions.

In conclusion, MARCKS1 is a gene that has the potential to be a drug target and biomarker for various diseases. Its role in the development and maintenance of tight junctions has been identified in a wide range of conditions, including cancer, neurodegenerative disorders, and autoimmune diseases. As more research is conducted on MARCKS1, it is likely that new treatments and diagnostic tests will be developed for these conditions.

Protein Name: MARCKS Like 1

Functions: Controls cell movement by regulating actin cytoskeleton homeostasis and filopodium and lamellipodium formation (PubMed:22751924). When unphosphorylated, induces cell migration (By similarity). When phosphorylated by MAPK8, induces actin bundles formation and stabilization, thereby reducing actin plasticity, hence restricting cell movement, including neuronal migration (By similarity). May be involved in coupling the protein kinase C and calmodulin signal transduction systems (By similarity)

The "MARCKSL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MARCKSL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets